IL36G

Across TCGA pan-cancer cohorts, IL36G Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL36G data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher IL36G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL36G expression acts as an unfavorable survival marker.

UCS, LIHC, and GBM are the cancer types where IL36G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
GBM	DFS	Median	All	0.064	0.257	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL36G–UCS (DFS)

Open the UCS breakdown →